# Cadonilimab in the Treatment of Advanced Soft Tissue Sarcoma

> **NCT05656144** · PHASE2 · UNKNOWN · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 49 (estimated)

## Conditions studied

- Soft Tissue Sarcoma

## Interventions

- **DEVICE:** Cadonilimab

## Key facts

- **NCT ID:** NCT05656144
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-02
- **Primary completion:** 2024-12
- **Final completion:** 2025-06
- **Target enrollment:** 49 (ESTIMATED)
- **Last updated:** 2022-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05656144

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05656144, "Cadonilimab in the Treatment of Advanced Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05656144. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*